Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.210 -0.140 (-3.22%)
Streaming Delayed Price Updated: 2:09 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
28 29 Next >
Psychedelic Stock Gainers And Losers From April 4, 2023
Via Benzinga
Compass Pathways Plc (NASDAQ: CMPS) Highlighted for Surprising Price Action
Via Investor Brand Network
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
5 Short Squeeze Stocks To Watch: Unicycle Therapeutics, Getty Images And More
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits... 
Via Benzinga
Where Compass Pathways Stands With Analysts
Via Benzinga
Largest Psychedelic Stocks -3.4% In March
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 31, 2023
Via Benzinga
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 29, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 28, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 27, 2023
Via Benzinga
10 Short Squeeze Candidates: Unicycle Therapeutics, Compass Pathways, Virgin Orbit Among Those To Watch
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
Cannabis Category Performances Ranged From +8.6% To -7.0% This Week
The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example. 
Via Talk Markets
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Atai Life Sciences Hopes Hercules Can Help 'Sustain' Operations Until 2026
Biopharma company Atai Life Sciences' (NASDAQ: ATAI) fourth quarter and full year 2022 consolidated financial results show: 
Via Benzinga
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 22, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 21, 2023
Via Benzinga
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
This is the third article of a three-part series, you can find the first and 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 20, 2023
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
The "Rags-To-Riches" Portfolio: An Update
Cannabis, psychedelic, and plant-based food stocks performed extremely poorly in 2022, down 73% vs. 2021 but perhaps some of them will bounce back with major returns in 2023. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 17, 2023
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression
COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TR 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback